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Abstract
 
Immature dendritic cells (iDCs) do not mature after uptake of apoptotic cells and may play a
role in the induction of peripheral tolerance to self antigens derived from apoptotic material.
 
The integrins, 
 
 
 
v
 
 
 
3, 
 
 
 
v
 
 
 
5, and the scavenger receptor, CD36, have been shown to mediate
uptake of apoptotic cells by iDCs. However, it is not known whether the complement system,
also takes part in this process. In this study we investigated the ability of iDCs to bind to apop-
totic cells opsonized by iC3b. Monocyte-derived dendritic cells were offered apoptotic Jurkat
 
cells opsonized by autologous iC3b and labeled with 1,1
 
 
 
-dioctadecyl-3,3,3
 
 
 
,3
 
 
 
-tetramethyl-
indocarbocyanineperchlorate. A significant increase (P 
 
  
 
0.001) in the amount of cleared apop-
totic cells was seen at low ratios. Despite increased efficiency of uptake, interaction between
iC3b-opsonized apoptotic cells and iDCs down-regulated the expression of major histocom-
patibility complex class II, CD86, CC chemokine receptor (CCR)2, CCR5, and 
 
 
 
2-integrins
(P 
 
  
 
0.001), and up-regulated expression of CCR7 (P 
 
  
 
0.001). In addition, iDC maturation
responses to CD40L and lipopolysaccharide were significantly inhibited. We conclude that
opsonization of apoptotic cells by iC3b induces tolerant iDCs that are able to migrate to
lymph nodes.
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Introduction
 
Immature dendritic cells (iDCs)
 
*
 
 engulf apoptotic cells and
are able to acquire antigens found in the dying cells (1–5).
Rubartelli et al., suggested that iDCs may use an integrin,
 
 
 
v
 
 
 
3, the vitronectin receptor, for uptake of apoptotic
cells (6). Albert et al. showed that another integrin, 
 
 
 
v
 
 
 
5
with the scavenger receptor CD36, both mediate uptake
of apoptotic cells by iDCs (7). Later, Nouri-shirazi et al.
suggested that iDCs may have subpopulations that use differ-
ent integrins (4).
The complement system has been shown to be activated
by human apoptotic material (for a review, see reference
8). We were able to show activation of both the classical
and alternative complement pathways by apoptotic cells
with opsonization by iC3b (9). Taylor et al. suggested a hi-
erarchical role for C1q in the ex vivo clearance of apop-
totic thymocytes by thioglycolate-derived peritoneal mu-
rine macrophages (10), and Ogden et al. showed a role for
CD91 and calreticulin in the uptake of apoptotic cells op-
 
sonized by mannose binding lectin and C1q (11). The
possible importance of complement-mediated opsonization
of apoptotic cells was further shown by the development of
systemic lupus erythematosus in 
 
 
 
90% of homozygous pa-
tients with C1q deficiency, in 75% of homozygous patients
with C4 deficiency, and by the development of glomerulo-
nephritis associated with increased apoptotic cells in the
glumeruli of C1q deficient mice (12). Cr2, a complement
degradation product receptor, found in mature B cells and
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in follicular dendritic cells, was recently reported as a can-
didate gene in the murine Sle1c lupus susceptibility locus
(13). Thus, C1q and complement degradation products
may take part in normal clearance of apoptotic cells and, as
such, may be involved in maintaining peripheral tolerance
induction to auto antigens found in apoptotic material.
In this work we studied the ability of iDCs to bind effi-
ciently to apoptotic cells opsonized by iC3b. Herein, we
show that opsonization of apoptotic Jurkat cells by autolo-
gous iC3b increased the efficiency of their uptake by iDCs
but inhibited maturation.
 
Materials and Methods
 
Media and Reagents.
 
Culture medium consisted of RPMI
1640, 1% 
 
l
 
-glutamine, 1% penicillin/streptomycin (Biological
Industries), 1% autologous human plasma, and recombinant hu-
man cytokines, GMCSF, and IL-4 (R&D Systems or Pepro-
Tech). Phosphatidylserine was stained by annexin-V-FITC
(R&D Systems). Mouse anti–human iC3b-PE was obtained
from Quidel Corp. Mouse anti–human CD11b-FITC, CD11c-
PE, CD14-APC, CD14-FITC, HLA-DR-FITC, CD1a-PE,
CD1a-FITC, and isotype controls were obtained from IQ Prod-
ucts. Mouse anti–human CD83-PE was obtained from Immuno-
tech, and mouse anti–human CD86-PE from Cymbus Biotech-
nology. CH11 was purchased at Upstate Biotechnology. PKH-
67, complement depleted serum, latex beads, and LPS were ob-
tained from Sigma-Aldrich, and 1,1
 
 
 
-dioctadecyl-3,3,3
 
 
 
,3
 
 
 
-tet-
ramethyl-indocarbocyanineperchlorate (DIL) was obtained from
Molecular Probes.
 
Dendritic Cells.
 
Immature monocyte-derived dendritic cells
were generated from the CD14
 
 
 
 selected fraction of PBMCs and
from blood donors buffy coats. iDCs were isolated as described
elsewhere (1) with modification in monocytes selection. Briefly,
PBMCs were isolated using Ficoll as described previously (9) and
anti-CD14 magnetic beads were used in order to isolate mono-
cytes from PBMCs according to the manufacturer’s instructions
(Miltenyi Biotech). Monocytes were placed in wells at a concen-
tration of 2.5 
 
 
 
 10
 
6
 
/3 ml culture media in the presence of 1% au-
tologous plasma, GMCSF (1,000 U/ml), and IL-4 (1,000 U/ml).
Every 2 d 0.3 ml were removed and 0.5 ml media containing
plasma, IL-4, and GMCSF, 500 U/ml, were added. By day 6,
 
 
 
90% of the cells were CD14
 
 
 
, with low expression of DR,
CD-83, and CD-86.
 
Staining Cells, Induction, and Detection of Apoptosis.
 
Apoptotic
cells were generated using a tumor cell line, Jurkat T cell lym-
phoma (9). Jurkat T cell lymphoma cells were washed with
RPMI in the absence of serum and stained with DIL according
to the manufacturer’s instructions. In some experiments cells were
stained with PKH-67. After staining, 2% FCS was added and the
cells were incubated at 37
 
 
 
C for 2.5 h for the induction of se-
rum-withdrawal apoptosis or 2.5 h with 0.5 
 
 
 
gr/ml, CH11, for
fas-induced apoptosis. Apoptosis was detected by double staining
with annexin-V-FITC and propidium iodide, as well as by the
percentage of hypodiploid region of propidium iodide stained
cells (14).
 
Opsonization by Complement.
 
Complement activation was shown
by measuring the release of C3a by ELISA (The Binding Site).
Complement opsonization with iC3b was verified using a FAC-
Scan™ (Becton Dickinson) and costaining of annexin-V-FITC
and iC3b-PE. In addition, membrane localization was evaluated
using confocal microscopy.
 
Interaction of Apoptotic Cells with iDCs.
 
Labeled apoptotic cells
were added to iDCs on day 6 of culture, for 1 or 2 h/37
 
 
 
C in 200
 
 
 
l volume of culture media in the presence or absence of 15%
autologous human serum or plasma or complement depleted se-
rum or heat inactivated serum or heat inactivated plasma. Heat
inactivation of serum or plasma was performed at 56
 
 
 
C for 30
min. In most assays, iDCs were labeled with CD1a-PE, or
CD14-APC. Uptake was read by a FACScan™ and validation of
the results was performed using PKH-67 for staining apoptotic
cells. Adhered, noninternalized apoptotic Jurkat cells were de-
tected using anti-CD3-FITC. In additional experiments, unla-
beled apoptotic cells were offered to iDCs and the expression of
membrane molecules was examined 2–48 h later. In some inter-
actions, 
 
 
 
CD11b (
 
 
 
CR3), 
 
 
 
CD11c (
 
 
 
CR4), or control mouse
IgG, were added. Uptake of latex beads (Sigma), was used as a
control for phagocytosis.
 
Stimulation of iDCs via CD40 and LPS.
 
iDCs were incubated
overnight with 10 
 
 
 
g/ml CD40L and 20 ng/ml IL-4 or 5 
 
 
 
g/ml
anti-CD40, or 2 ng/ml LPS, and the expression of DR and
CD86 was evaluated. In inhibition experiments, iDCs were first
exposed for 2 h to apoptotic cells and then exposed to CD40L or
anti-CD40, or LPS.
 
Statistics.
 
Student’s 
 
t
 
 test was used to compare uptake and
Kolmogorov-Smirnov analysis was used to compare the expres-
sion of surface receptors on iDCs.
 
Results
 
The conditions for serum-withdrawal apoptosis were se-
lected because 60–70% of cells were annexin-V positive
and 
 
 
 
7% were positive for propidium iodide staining (un-
published data). Activation of complement by apoptotic
Jurkat cells was shown previously by us and by others (9,
15, 16). However, in order to verify that apoptotic Jurkat
cells can activate complement under the specific conditions
that we used for induction of apoptosis, we measured re-
lease of C3a in the supernatants. C3a release measured in
the supernatants of interacting iDCs and apoptotic Jurkat
cells was found to be 1,990 
 
 
 
198 ng/ml in the presence of
15% fresh serum as compared with 220 
 
 
 
 38 when the in-
teraction occurred in the presence of heat-inactivated se-
rum (P 
 
  
 
0.001). To further verify that apoptotic cells
were opsonized by iC3b we stained apoptotic Jurkat cells
for iC3b deposition and found membrane staining using
confocal microscopy (Fig. 1). These results were verified
using flow cytometry, where deposition of iC3b was
shown in 
 
 
 
90% of annexin-V–positive cells but in 
 
 
 
3% of
annexin-V–negative cells (not shown).
We generated iDCs that were 
 
 
 
90% CD14
 
 
 
CD1a
 
 
 
, as
well as low DR, CD83, and CD86 (see below). To deter-
mine whether complement activation increased uptake of
apoptotic cells, we measured uptake by iDCs by FAC-
Scan™ using similar methodology to that described (4, 7,
17), and as explained in Fig. 2. As shown in Fig. 3 A, at a ra-
tio of 1:1, iDC:apoptotic cell, 44.25 
 
 
 
 2.21% of iDCs
bound/engulfed apoptotic Jurkat cells in the absence of se-
rum compared with 83.25 
 
 
 
 4.3%, in the presence of serum
(P 
 
  
 
0.001, triplicates, representative of six experiments). At
a ratio of 1:2 the gap decreased but there was still a signifi-
cant difference in all experiments, 59.2 
 
 
 
 4.3% versus 93 
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5.3%, respectively (P 
 
  
 
0.001). However, at 1:4 there was a
further decrease and the difference was nonsignificant in one
out of six experiments. At ratios of 1:8 and 1:16 there was
no difference in the number of iDCs that bound/engulfed
apoptotic Jurkat cells in the absence or presence of autolo-
gous fresh serum. To further evaluate the relative number of
apoptotic cells bound or engulfed by iDCs, we used the me-
dian fluorescence of DIL detected in the area of the gated
iDCs. As shown in Fig. 3 B, median fluorescence, at a ratio
of 1:1, was increased up to eightfold in the presence of au-
tologous serum. This difference decreased gradually upon
increasing the ratio but was still elevated (1.3–1.8-fold) at a
ratio of 1:16. To further verify that this effect was due to
complement activation we simultaneously examined inter-
actions with autologous heat-inactivated serum. Heat-inac-
tivation abolished the effect of serum, the result being simi-
lar to that seen in the absence of serum (Fig. 3, C and D).
The experiments were repeated using autologous plasma in-
stead of serum, with similar results (not shown). To verify
that all interacting cells were phagocytosed, staining with
Figure 1. Apoptotic Jurkat cells are opsonized by iC3b. Jurkat cells were induced to undergo serum withdrawal apoptosis, followed by incubation and
exposure to 15% fresh serum from donor dendritic cells for 1 h/37 C/5% CO2. Cells were stained with annexin V-FITC (A), or iC3b-PE (B). As seen
by confocal microscopy (Nomarsky, 40, zoom  2), cells show membranous staining of both Phosphatidylserine and iC3b. Viable cells or apoptotic cells
exposed to heat-inactivated serum did not stain for iC3b.
Figure 2. Evaluation of interaction be-
tween iDCs and apoptotic Jurkat cells using
flow cytometry. (Left) Jurkat cells were
stained with DIL and then were induced to
undergo apoptosis. DIL-stained apoptotic
cells (bold line) and unstained apoptotic
cells (solid line) are shown. (Middle) When
iDCs and Jurkat cells were incubated to-
gether at 4 C, immediately before flow cy-
tometry acquisition, two subpopulations
were recognized. R1 consisted of  93%
CD1a CD3 DIL  cells, whereas R2 shows
 94% CD1a CD3 DIL  cells. Thus, R1
determined population of noninteracting iDCs and R2 determined population of unbound Jurkat cells. During a 2-h interaction between iDCs and DIL-
stained apoptotic Jurkat cells at 37 C, iDCs, acquired DIL from bound or phagocytosed apoptotic cells. Thus, after interaction at 37 C, R1 contains both
noninteracting iDCs and interacting iDCs. (Right) R1 of the former figure after a 2-h interaction between iDCs and DIL-stained apoptotic Jurkat cells,
at 37 C. Most of the interacting iDCs (bold line) acquired DIL in this experiment as compared with unstained iDCs (dotted line). iDCs that did not
bound or phagocytosed apoptotic cells are found in the area of unstained iDCs. During 2 h of interaction no passive staining of iDCs occurred as demon-
strated by 2 chambers incubation (not shown). The percentage of interacting iDCs that acquired DIL, as well as, mean and median fluorescence, were
measured. The interaction was performed in different iDC:Jurkat ratios and in the presence or absence of fresh serum or heat inactivated serum. In inhi-
bition studies, iDCs were preincubated with monoclonal antibodies for 30 min before interaction. To distinguish between bound apoptotic Jurkat cells
and internalized cells, we stained with anti-CD3-FITC and determine what percentage of iDCs that acquired DIL, stained for CD3. CD3, expressed on
apoptotic Jurkat cells (and not on iDCs), stained only noninternalized, adhered, apoptotic Jurkat cells. Similar results were obtained upon validation of
this system, using Jurkat cells stained with PKH, or double staining of CD1a-FITC, DIL-apoptotic Jurkat cells. 
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Figure 3. Interaction of apoptotic cells with iDCs is facilitated by autologus complement and complement receptors. After 2 h of incubation with ap-
optotic cells, iDCs were analyzed for interaction using flow cytometry as explained in Fig. 2. (A) The percentage of iDCs that interacted with DIL-
stained, iC3b-opsonized, apoptotic cells, is given for different ratios of iDCs:apoptotic cells. (B) Median fluorescence of DIL as expressed in iDCs is given
for different ratios. (C and D) Heat-inactivation abolished the effect of serum seen in A and B, and brought it to the level of interaction seen in the ab-
sence of serum. Average of triplicates measures is given (error bars). Representative of six experiments. (E) iDCs express CD11b/CD18 and CD11c/
CD18 (iDC, bold line). Marked down-regulation of both CD11b/CD18 and CD11c/CD18 but not in CD1a, was observed after interaction with iC3b-
opsonized apoptotic cells (iDC apo, bold line). (F) 91% of iC3b-opsonized apoptotic cells were cleared by iDCs (None). No significant increase in the
remaining noncleared apoptotic cells was seen when control mouse IgG was added (mIgG), compared with significant, 53% inhibition, in clearance seen
when  CD11b (P   0.05), or  CD11c (46% inhibition, P   0.05), or both (59% inhibition, P   0.01), were added. Representative of six experiments.
DC, dendritic cells; MF, median fluorescence; NS, no serum, i.e., apoptotic cells were not exposed to fresh serum from iDC donor; S, serum, i.e., apop-
totic cells were exposed to 15% fresh serum from iDC donor. 
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anti-CD3 was performed. 2 h after interaction, between 18–
35% of the interacting cells still had bound Jurkat cells (at ra-
tio 1:4). However, by 18 h after the interaction, 
 
 
 
10% of
iDCs that acquired DIL, stained for CD3.
CD11b/CD18 and CD11c/CD18 are known receptors
for complement degradation products and as shown in Fig.
3 E, all iDCs expressed the complement receptors with
marked down-regulation of these receptors after exposure
to iC3b-opsonized apoptotic cells. To test the role of 
 
 
 
2
integrins in mediating interaction with apoptotic cells we
further exposed iDCs to monoclonal antibodies to these re-
ceptors before interaction with iC3b-opsonized apoptotic
cells. As shown in Fig. 3 F, uptake of apoptotic cells by
iDCs was significantly reduced when exposed to 
 
 
 
CD11b/
CD18 and 
 
 
 
CD11c/CD18 but not to control antibody.
Next we attempted to verify that the increased uptake of
iC3b opsonized apoptotic cells did not induce maturation
of iDCs. iDCs were stained for CD1a, DR, CD83, and
CD86, before and after exposure to apoptotic cells op-
sonized by autologous iC3b. In Fig. 4 A, we show that iDC
did not up-regulate surface DR or CD86 (as well as CD83,
not shown) after uptake of apoptotic cells opsonized by
iC3b. In fact, as shown in Fig. 4 A, in most experiments we
observed down-regulation of DR and CD86. In addition,
we measured IL-12 secretion in supernatants of iDCs ex-
posed to opsonized apoptotic cells. No increase in baseline
level was observed in up to 48 h (data not shown). To fur-
ther test whether iDCs exposed to iC3b-opsonized apop-
totic cells were in a state of anergy we exposed iDCs to
CD40L or to anti-CD40. We observed marked inhibition
of the maturation response to CD40L after exposure to
iC3b-opsonized apoptotic cells (see Fig. 4 B). Remarkably,
in most experiments, the expression of DR and CD86 was
down-regulated to levels below levels that were seen in
iDCs that were not exposed to CD40L. This immune-
paralysis induced by apoptotic cells was shown also during
LPS administration (Fig. 4 C). However, LPS-induced in-
hibition was to the basic levels of iDCs. Uptake of latex
particles did not inhibit maturation after LPS and did not
down-regulate the expression of CD86 and MHC class II
with median fluorescence of 88 and 124, after phagocytosis,
and 91 and 118 without phagocytosis, respectively.
We further strove to determine whether the down-regu-
lation of maturation molecules such as CD86, CD83, and
MHC class II was linked to the absence CCR7-mediated
migration to lymph nodes. We were surprised to see, as
shown in Fig. 5, that after interaction with autologous iC3b-
opsonized apoptotic Jurkat cells, iDCs demonstrated mild
but significant up-regulation in the expression of CCR7 but
down-regulation of CCR2 or CCR5. Phagocytosis of latex
beads did not up-regulate the expression of CCR7 as me-
dian fluorescence was 3.66
 
 
 
 0.8 in iDCs and 3.88
 
 
 
 0.92 af-
ter phagocytosis of latex beads (three experiments).
Taken together, activation by complement and op-
sonization of apoptotic cells by autologous iC3b, were as-
sociated with a significant increase in uptake by iDCs at
low ratios of iDCs:apoptotic cells. This effect not only was
not associated with “maturation,” but rather, induced
down-regulation of MHC class II and CD86, as well as
CCR2, CCR5, CD11b/CD18, and CD11c/CD18. De-
spite lack of classical maturation, iDCs expressed CCR7.
 
Discussion
 
As a part of innate immunity, the main purpose of op-
sonization by complement was traditionally ascribed to
Figure 4. Apoptotic cells opsonized by iC3b, down-regulate MHC
class II and CD86, and immune-paralyze the effect of CD40L or LPS, on
iDCs. (A) Expression of DR-FITC and CD86-PE (bold lines) on iDCs
were down-regulated upon exposure to apoptotic cells (solid lines, me-
dian fluorescence 67 to 40, and 54 to 17, respectively, P   0.001). (B)
DR-FITC and CD86-PE, expressed on iDCs (bold lines, median fluores-
cence 62, and 22, respectively), were up-regulated (gray lines, median
fluorescence 133, and 58, respectively, P    0.001) after exposure to
CD40L. However, if iDCs were exposed to apoptotic cells, before
CD40L (solid lines), up-regulation was inhibited (median fluorescence
7.4, and 7.84, respectively. P   0.001). (C) Similarly to CD40L, DR-
FITC, and CD86-PE, expressed on iDC (bold lines, median fluores-
cence, 57 and 55, respectively), were up-regulated (gray lines, median
fluorescence 80, and 117, respectively. P   0.001), after exposure to LPS.
Again, if iDCs were exposed to apoptotic cells, before LPS (solid lines),
up-regulation was inhibited (median fluorescence 60, and 71, respec-
tively; P   0.001).1558 Dendritic Cells Interaction with iC3b-opsonized Apoptotic Cells
coating of microorganisms that penetrated the mammalian
sterile milieu with subsequent clearance of opsonized parti-
cles by specific receptors on the surface of leukocytes.
Thus, in this context, the requirement for complement ac-
tivation to ensure efficient uptake of apoptotic cells by
iDCs, appears contrary to the notion that phagocytosis of
apoptotic cells is a noninflammatory process (18, 19).
However, as shown here, opsonization of apoptotic cells by
iC3b down-regulated the expression of MHC class II or
CD86 on iDCs, and therefore would not be expected to
increase T cells priming and autoimmunity in “normal”
circumstances, and may actually have a role in maintaining
tolerance in a steady-state (20, 21).
A role for complement and complement receptors in
clearance of apoptotic cells by macrophages, have been
shown previously (9–11, 16, 22). As shown here, the use of
ratios equal to or higher than 1:8 could miss this effect.
Furthermore, using the number of phagocytes participating
in uptake rather than the actual relative number of apop-
totic cells being bound or engulfed, masks the complement
contribution, even at ratios of 1:4. When total bound/en-
gulfed apoptotic cells were measured, as expressed in me-
dian fluorescence, the complement effect was still evident
at 1:8. These observations may provide an explanation for
the findings in some previous studies that used high ratios
or percentage of phagocytic cells for evaluation of uptake,
and in which serum or complement did not seem to have
an effect. In addition, when certain batches of sera were
used, we noted inhibitory effects on phagocytosis that were
eliminated only when we used autologous sera. Thus, the
use of nonautologous sera may have both a facilitating ef-
fect related to complement and an inhibitory effect of un-
certain cause.
CD11b/CD18 and CD11c/CD18 that were shown to
be receptors for iC3b (23) may function in several ways.
First, in adhesion as down-regulation of CD11b/CD18 and
CD11c/CD18 may facilitate de-adhesion and migration.
Second, as shown in this study, opsonization of apoptotic
cells by iC3b may facilitate peripheral or tissue specific self-
antigen capture either by tethering, phagocytosis, or both.
It may also help to compete with less potent APCs like B
cells that do not express CD11b/CD18 and CD11c/CD18
at the level of lymph node. Third, integrins also elicit signal
transduction events (for a review, see reference 24). Liga-
tion of iC3b-opsonized particles to complement receptors
does not have a proinflammatory effect and was shown to
signal for an antiinflammatory response, as demonstrated by
down-regulating IL-12 and  -interferon production by
human monocytes (25–27). In addition, binding and phago-
cytosis via macrophage CD11b/CD18, did not trigger a re-
spiratory burst (28, 29), or leukotriene release (30). Trans-
dominant suppression was described for  v 5 by ligand to
integrin receptor (31) and it is not known if, similarly, liga-
tion of  2 integrins may mediate down-regulation of phago-
cytic function or surface expression of molecules such as
CD86 or MHC class II. Fourth, iDCs that capture apop-
totic material were suggested to be short-lived dendritic
cells (32) but ligation of integrins may serve as an antiapop-
totic signal (33). Indeed, CD11b/CD18-deficient granulo-
cytes are relatively protected from apoptosis (34). Fifth,  2
integrin are known for their bacteria and LPS binding
properties (35), and down-regulation may avoid interac-
tions that lead to proinflammatory consequences and re-
cruitment to inflammatory sites.
Some limitation of our study are noteworthy. First, it is
possible that the function of complement receptors and
CD36 represent adherence or tethering whereas other re-
ceptors described, such as  v 5,  v 3, Mer, or the phos-
phatidylserine receptor (36), mediate phagocytosis. We did
not directly address the question as to whether complement
facilitation is mediated by increased adherence or increased
phagocytosis but we were able to show that complement
enhanced interaction of apoptotic cells with iDC and that by
16–18 h  90% of cells were internalized, at low ratios. In
addition, cytokines, chemokines, autacoids, and other factors
may function in tethering and/or engulfment. In the same
line, phagocytosis of apoptotic cells involves a complex of
receptors and we cannot attribute the down-regulation of
costimulatory receptors only to the presence of complement
degradation products or ligation of complement receptors.
Second, it is possible that some cells and/or some modes of
apoptosis do not activate complement and therefore some
apoptotic cells are neither opsonized nor bound nor en-
gulfed through a complement–dependent mechanism.
Figure 5. CCR7 is expressed
on iDCs after interaction with
iC3b-opsonized apoptotic cells.
iDCs were stained for the ex-
pression of chemokines receptors
(bold lines), CCR2, CCR5, and
CCR7 and compared with iDCs
that were exposed to apoptotic
cells (solid lines). On day 6, iDCs
stained for CCR2 and CCR5
but not for CCR7. Upon expo-
sure to opsonized apoptotic cells
marked down-regulation of
CCR2 and CCR5 was ob-
served (median fluorescences
were down-regulated (from 9.14 to 1.88, and from 21 to 1.55, respectively, P   0.001). In contrast, median fluorescent of CCR7 was up-regulated from
3.31 to 6.92 (P   0.001). Representative of four experiments. Range of up-regulation of CCR7, 60–300% increase.1559 Verbovetski et al.
iDCs ingest antigens by phagocytosis, macropinocytosis
or receptor-mediated endocytosis. After ingestion, iDCs
are triggered to undergo a developmental program called
maturation (37). In this study we were able to show that af-
ter interaction with apoptotic cells, iDCs not only did not
up-regulate, but rather down-regulated MHC class II and
CD86, emphasizing the possible role of dendritic cells in
inducing anergy rather than priming autoimmune T cells.
This is further illustrated by the state of anergy of iDCs ex-
posed to iC3b-opsonized apoptotic cells that did not up-
regulate MHC II and CD86 when stimulated by CD40L
or LPS and by the lack of IL-12 secretion. The mechanism
of down-regulation of CD86 and MHC class II is not
known but could be related, in the case of MHC class II, to
the high capacity of endocytosis (38), or by regulation of
proteolysis by cytokines (39).
An additional functional modification, usually attributed
to mature dendritic cells, is the ability to migrate from pe-
ripheral tissues to secondary lymphoid organs, achieved
through the modification of chemokine receptors, most
notably, the up-regulation of CCR7 (EBI1; references 40–
43). CCL19 (MIP-3 , ELC), a ligand for CCR7, have
been shown to be expressed in various lymphoid tissues
(44–46) and in T cell–rich area of lymph nodes (42). Fur-
thermore, CCL19 expression was restricted to paracortical
areas, where either generation of primary T cell response or
tolerance is induced. As CCR7 was reported to be ex-
pressed mainly in mature dendritic cells, a question that
arises is, how might anergised “immature” dendritic cells
migrate to lymph nodes in order to tolerize T cells (20,
21)? In this study, CCR7 was weakly expressed on iDCs
on day 6 and was up-regulated after exposure to apoptotic
cells despite the absence of maturation properties. Indeed,
CD14-derived iDCs showed a weak but clear migratory
response to CCL19 (47), and bone marrow–derived mu-
rine dendritic cells expressed CCR7 even in the absence of
 CD40 treatment (48). On the other hand, Yanagihara et
al. showed that CD14 -derived iDCs did not migrate in
response to CCL19 (40), when CD86  iDCs were used.
The present study and the former observations lead us to
suggest that “young” iDCs, characterized by CD86absent
(40), do not express CCR7 and do not migrate toward
CCL19. However, iDCs, defined by CD86lowDRlow that
were perhaps exposed to apoptotic dendritic cells during
the 6 d of incubation (unpublished data), weakly up-regu-
late CCR7. It is tempting to speculate that CCR7-express-
ing iDCs that ingested apoptotic material may migrate to
peripheral lymph nodes, constitutively, and at a lower rate
(where opsonization by complement is most efficient)
compared with inflammatory stimuli, in order to maintain
tolerance (20, 21, 32). Further studies are needed in order
to determine whether responsiveness to CCR7 chemo-
kines is functional.
The pro-, non, or antiinflammatory consequences of
complement activation via complement receptors likely
depend upon the specific ligands encountered, the coliga-
tion of other receptors such as Toll receptors and FcR, the
presence of molecules such as CRP and factor H (16), and
the extent of generation of active fragments such as C3a,
C5a, and membrane attack complex. Ligation of CD11b/
CD18 and CD11c/CD18, receptors for iC3b-opsonized
apoptotic cells, probably represent an antiinflammatory or
noninflammatory consequence of limited complement ac-
tivation (9). On the other hand, due to the great potential
of iDCs in priming an immune response, a great danger of
autoimmunity exists (21) in the presence of a proinflam-
matory milieu. Proinflammatory milieu may include
ligands for Toll receptors, proinflammatory cytokines as
found in conditioned media, absence of facilitating factors
such as complement proteins, or the presence of autoanti-
bodies (17). Opsonization by IgG autoantibodies rather
than natural IgM autoantibodies may lead to uptake via
Fc R that was shown to promote iDC maturation, pre-
sentation on both MHC class I and II molecules, and
priming of both CD4  helper and CD8  cytotoxic T lym-
phocytes (49). Any of these conditions and other un-
known ones may shift the limited complement activation
to full activation with generation of C5 convertase, C5a,
and membrane attack complex. These may dictate higher
expression of MHC class II and costimulatory molecules in
interacting iDCs and may cause priming of autoimmune T
cell clones in lymph nodes. This may be a possible mecha-
nism for persisting inflammation or accelerating autoim-
munity in diseases such as systemic lupus erythematosus
(22) or may even explain the increased autoimmunity seen
in diseases such as AIDS, in which a high turnover of apop-
totic cells exists.
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